Last reviewed · How we verify
NCT06228209: TIER-PC
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
NA trial testing Tier - Palliative Care in Advanced Heart Failure in 60 participants. Enrolling by invitation.
19 August 2026
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 60 |
| Start date | 31 January 2025 |
| Primary completion | 19 August 2026 |
| Estimated completion | 19 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tier - Palliative Care
Conditions studied
- Advanced Heart Failure — all drugs for Advanced Heart Failure →
- Advanced Non-colorectal Gastro-intestinal Cancer — all drugs for Advanced Non-colorectal Gastro-intestinal Cancer →
- Advanced Lung Cancer — all drugs for Advanced Lung Cancer →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with Advanced Heart Failure or Advanced Non-colorectal Gastro-intestinal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines. In Tier 1, patients who are able to care for themselves and no/mild symptoms receive a community health worker (CHW) trained to elicit illness understanding in a culturally competent way. In Tier 2, for patients with poorer function and mild symptoms, a social worker (SW), trained in serious illness communication, joins the CHW to further elicit patients' goals and prognostic understanding while communicating symptom needs to their primary clinician. In Tier 3, as function decreases and symptoms increase, an advance practice nurse (APN) joins the CHW and SW to manage complex symptoms. Finally, in Tier 4, for those older adults with the poorest function and most complex symptoms, a physician joins the team to ensure that the most complex needs (e.g., end-of-life treatment preferences and multifaceted symptom control) are met. The CHW follows patients longitudinally across all tiers and re-allocates them to the appropriate tier based on their evolving needs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06228209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Heart Failure
Currently open trials in the same condition.
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06228209 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06228209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing